| RCMTX | TRRNX | RCMTX / TRRNX | |
| Total Expense Ratio | 1.02 | 0.63 | 162% |
| Annual Report Gross Expense Ratio | 1.02 | 0.63 | 162% |
| Fund Existence | 16 years | 20 years | - |
| Gain YTD | 7.784 | 10.290 | 76% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 2500 | 10% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 31.8B | 12B | 265% |
| Annual Yield % from dividends | 0.23 | 1.14 | 20% |
| Returns for 1 year | 9.67 | 15.78 | 61% |
| Returns for 3 years | 42.68 | 46.73 | 91% |
| Returns for 5 years | 24.06 | 27.46 | 88% |
| Returns for 10 years | 103.86 | 107.29 | 97% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GTHIX | 40.70 | 0.54 | +1.34% |
| Invesco Health Care Invstor | |||
| AAGOX | 115.05 | N/A | N/A |
| Alger Large Cap Growth I-2 | |||
| GSPKX | 19.88 | N/A | N/A |
| Goldman Sachs US Eq Div and Prem Instl | |||
| RNNEX | 76.91 | -0.98 | -1.26% |
| American Funds New Economy R-2E | |||
| MCYAX | 15.47 | -0.62 | -3.85% |
| NYLI Candriam Emerging Markets Eq Cl A | |||